This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

What's in Phil Mickelson's Portfolio? Clorox, Barclays and 3 More He Endorses

Amgen (AMGN) ($119.12) and Pfizer (PFE) (29.56) jointly market Enbrel the drug Phil uses to treat his symptoms of psoriatic arthritis. Amgen is trading above its 200-day SMA at $116.01 after setting an all-time high at $128.96 on march 21. Pfizer is trading below its 200-day SMA at $30.47 after setting a multiyear intraday high at $32.96 on March 6.

Amgen has a positive weekly chart with its five-week MMA at $115.50 while Pfizer has a negative weekly chart with its five-week MMA at $29.97. The technicals thus favor Amgen over Pfizer.

Amgen has a semiannual value level at $102.54 with a monthly risky level at $122.38. Pfizer has an annual value level at $23.35 with semiannual pivots at $28.78 and $29.20 with a monthly risky level at $33.10.

Barclays (BCS) ($16.19) is below its 200-day SMA at $16.62 and has a negative weekly chart with its five-week MMA at $16.57 and 200-week SMA at $15.07. Semiannual; value levels are $13.70 and $12.74 with a quarterly pivot at $16.61 and monthly risky level at $17.06. Good endorsement, sell the stock.

Exxon Mobil (XOM) ($100.23) set an all-time intraday high at $103.45 on May 7 but its weekly chart shifts to negative given a close this week below its five-week MMA at $100.04. A semiannual value level is $91.91 with a semiannual pivot at $100.97 with an annual risky level at $108.71. Use the fuel, sell the stock.

At the time of publication the author held no positions in any of the stocks mentioned.

Follow @Suttmeier

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff

Richard Suttmeier is the chief market strategist at .
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CLX $129.25 -0.14%
ELY $9.42 -0.79%
AAPL $94.25 -0.98%
FB $118.11 0.58%
GOOG $696.80 0.64%


Chart of I:DJI
DOW 17,668.69 -82.22 -0.46%
S&P 500 2,051.97 -11.40 -0.55%
NASDAQ 4,728.9080 -34.3160 -0.72%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs